-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices
•
Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals from Chinese regulatory authorities for its innovative heart pulse electric field ablation device and disposable heart pulse electric field ablation catheter. These products, when used in tandem, employ the non-thermal effects of pulsed electric fields…
-
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
•
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and international, have revised the pricing of their thoracic aortic stent graft products. Among these companies are the US-Irish firm Medtronic (NYSE: MDT), Shanghai-based MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), W. L. Gore & Associates,…
-
Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities
•
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent surgical stapler, the Signia Stapler, in China. This new device is set to enhance surgical procedures with its advanced features. Originally designed for open surgery, the stapler’s application scenarios have expanded to include laparoscopic surgery,…
-
Medtronic’s Advanced Mazor X Spinal Surgery Robot Receives Chinese Market Clearance
•
Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approval from Chinese authorities for its fully upgraded Mazor X spinal surgery robot integrated platform. This marks a significant milestone for the company’s advanced surgical solutions in the Chinese market. Initially launched in China in 2021,…
-
Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval
•
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal denervation (RDN) system has become the first of its kind to receive market approval from China’s National Medical Products Administration (NMPA). The company celebrates this milestone, which positions it at the forefront of the RDN…
